It can be concluded that EAM-2201 has the possible to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes.The computed facts are compared Together with the available 1st principle calculations and experimental knowledge, exhibiting s